| 骆牡丹.血清FGF21，TSP2表达与老年慢性心衰患者心室重构的相关性[J].浙江中西医结合杂志,2026,36(2): |
| 血清FGF21，TSP2表达与老年慢性心衰患者心室重构的相关性 |
|
| 投稿时间：2024-12-09 修订日期：2025-06-09 |
| DOI： |
| 中文关键词: 慢性心衰 成纤维细胞生长因子21 血小板反应蛋白2 心室重构 |
| 英文关键词:Chronic heart failure Fibroblast growth factor 21 Thrombospondin 2 Ventricular remodeling |
| 基金项目:金华市科学技术研究计划项目(2021-4-089) |
|
| 摘要点击次数: 66 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【】目的:探讨血清成纤维细胞生长因子21(FGF21),血小板反应蛋白2(TSP2)表达与老年慢性心衰患者(CHF)心室重构的相关性。方法:选取本院105例CHF患者为CHF组,根据是否发生心室重构分为心室重构组(32例)和非心室重构组(73例)；同期选取100例体检健康者为对照组。检测血清FGF21和TSP2水平,并分析心室重构CHD患者血清FGF21、TSP2之间的相关性及其与超声心动图参数左心房内径(LAD)、左心室后壁厚度(LVPWT)、左心室舒张末期容积(LVEDV)的相关性；Logistic回归分析CHD患者发生心室重构的影响因素；受试者工作特征(ROC)曲线分析血清FGF21、TSP2对CHD患者发生心室重构的预测价值。结果:CHD患者血清FGF21、TSP2水平显著升高(P＜0.05)；心室重构患者血清FGF21与TSP2水平呈正相关(r=0.498,P＜0.05)；血清FGF21与LAD、LVPWT、LVEDV、LVMI呈正相关(r=0.428、0.416、0.523、0.474,P＜0.05),血清TSP2与LAD、LVPWT、LVEDV、LVMI呈正相关(r=0.456、0.469、0.507、0.407,P＜0.05)；LVEDV、FGF21、TSP2为CHD患者发生心室重构的危险因素(P＜0.05)；血清FGF21和TSP2单独及联合预测心室重构发生的AUC分别为0.823、0.866、0.937,联合预测效果更佳(Z联合-FGF21=2.906、P=0.004,Z联合-TSP2=2.191,P=0.029)。结论:CHD患者血清FGF21、TSP2水平升高,高水平FGF21、TSP2与CHD患者心室重构的发生有关,且二者联合检测对预测心室重构具有较高临床价值。 |
| 英文摘要: |
| Objective: To investigate the correlation between serum fibroblast growth factor 21 (FGF21), thrombospondin 2 (TSP2) expression and ventricular remodeling in elderly patients with chronic heart failure (CHF). Methods: Totally 105 CHF patients in our hospital were regarded as CHF group, and were assigned into ventricular remodeling group (32 cases) and non ventricular remodeling group (73 cases) based on whether ventricular remodeling occurred. During the same time, 100 healthy individuals who underwent physical check ups were as control group. The levels of serum FGF21 and TSP2 were measured, and the correlation between serum FGF21 and TSP2, and their correlation with echocardiographic parameters such as left atrial diameter (LAD), left ventricular posterior wall thickness (LVPWT), and left ventricular end diastolic volume (LVEDV) were analyzed in CHD patients with ventricular remodeling. Logistic regression was used to analyze the influencing factors of ventricular remodeling in CHD patients. Receiver operating characteristic (ROC) curves were used to analyze the predictive value of serum FGF21 and TSP2 for ventricular remodeling in CHD patients. Results: Serum FGF21 and TSP2 were greatly increased in CHD patients (P<0.05). There was a positive correlation between serum FGF21 and TSP2 in patients with ventricular remodeling (r=0.498, P<0.05). Serum FGF21 was positively correlated with LAD, LVPWT, LVEDV, and LVMI (r=0.428, 0.416, 0.523, 0.474, P<0.05), while serum TSP2 was positively correlated with LAD, LVPWT, LVEDV, and LVMI (r=0.456, 0.469, 0.507, 0.407, P<0.05). LVEDV, FGF21, and TSP2 were risk factors for ventricular remodeling in CHD patients (P<0.05). The AUC values of serum FGF21 and TSP2 alone and combination for predicting ventricular remodeling were 0.823, 0.866, and 0.937, respectively. The combined prediction effect was better (Z combination - FGF21=2.906, P=0.004, Z combination - TSP2=2.191, P=0.029). Conclusion: Serum FGF21 and TSP2 are elevated in CHD patients. High levels of FGF21 and TSP2 are associated with the occurrence of ventricular remodeling in CHD patients. The combined detection of the two has high clinical value in predicting ventricular remodeling. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
